Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Part of paid clinical trials in Los Angeles, California.

Sponsor
Pfizer
Study ID
NCT01710046
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • (CP-6890,550) Tofacitinib — DRUG
    2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
  • Placebo — DRUG
    2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
  • (CP-690,550) Tofacitinib — DRUG
    2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
  • Placebo — DRUG
    2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

Study Details

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

Key Dates

Start date
Mar 31, 2013
Status verified
Mar 2015
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
  • Experimental: Cohort 2

Primary Outcome Measure

Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12 [ Time Frame: Week 12 ]

Locations (5)

FacilityCityStateZIPSite coordinators
Dermatology Research AssociatesLos AngelesCalifornia90045-
Olympian Clinical ResearchTampaFlorida33609-
Menter Dermatology Research InstituteDallasTexas75246-
Center for Clinical StudiesHoustonTexas77004-
Center for Clinical StudiesHoustonTexas77030-

Find similar trials in Los Angeles, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Dermatology Research Associates· Los Angeles, CAOlympian Clinical Research· Tampa, FLMenter Dermatology Research Institute· Dallas, TXCenter for Clinical Studies· Houston, TX

Related Studies